Garcinia Mangostana Extracts in the Management of Weight Loss
Kľúčové slová
Abstrakt
Popis
After the screening visit for the evaluation of the inclusion / exclusion criteria and sign informed consent(Visit 1), each patient will be randomized (Visit 2; Time 0; Baseline) (1: 1) to receive two different treatment for the duration of 26 weeks:
1. low-calorie balanced diet consistent exercise (control group)
2. balanced low-calorie diet and regular exercise in combination with the assumption of Garcinia mangostana (treatment group)
Throughout the duration of the study, every eight weeks, unless otherwise indicated from the specialists, for each subject was expected a nutritional and an endocrinological visit with a anthropometric parameter check (body composition) and compliance to therapy (dietary / physical activity diary).
Also a bood sample test was performed to evaluate electrocardiogram, lipid profile, glucose tolerance, hormonal parameters, inflammatory and bone markers.
Termíny
Naposledy overené: | 05/31/2016 |
Prvý príspevok: | 06/22/2016 |
Odhadovaná registrácia bola odoslaná: | 06/29/2016 |
Prvý príspevok: | 07/05/2016 |
Posledná aktualizácia bola odoslaná: | 08/29/2016 |
Posledná aktualizácia bola zverejnená: | 08/30/2016 |
Aktuálny dátum začatia štúdie: | 10/31/2015 |
Odhadovaný dátum dokončenia primárneho okruhu: | 04/30/2016 |
Odhadovaný dátum dokončenia štúdie: | 04/30/2016 |
Stav alebo choroba
Intervencia / liečba
Dietary Supplement: Garcinia mangostana (treatment group)
Behavioral: Control group
Fáza
Skupiny zbraní
Arm | Intervencia / liečba |
---|---|
Active Comparator: Garcinia mangostana (treatment group) Balanced low-calorie diet and regular exercise in combination with integration | Dietary Supplement: Garcinia mangostana (treatment group) |
Other: Control group balanced low-calorie diet and regular exercise | Behavioral: Control group |
Kritériá oprávnenosti
Vek vhodný na štúdium | 18 Years To 18 Years |
Pohlavia vhodné na štúdium | All |
Prijíma zdravých dobrovoľníkov | Áno |
Kritériá | Inclusion Criteria: - Obesity: BMI >35 kg/m2. - Stable medical therapy for comorbidities from at least 6 months Exclusion Criteria: - Hormonal replacement therapy - Hyperprolactinaemia and /or other endocrine hypothalamic-pituitary diseases (empty sella syndrome and expansive pituitary disorders evaluated by MRI) - Any other condition that medical judgment precludes patient safety |
Výsledok
Primárne výstupné opatrenia
1. Weight loss - Kg reduction [26 weeks]
Opatrenia sekundárnych výsledkov
1. Insulin sensitivity assessed by the homeostatic model assessment (HOMA-IR) [26 weeks]
2. Lipid profile by serum biochemistry [26 weeks]
3. Abdominal obesity measured by waist circumference [26 weeks]
4. Body composition by Dexa parameters [26 weeks]
5. Changes in microalbuminuria by unin analysis [26 weeks]